Amlexanox

NMD inhibitor leading to full-lenght protein synthesis from nonsense mutation-containing RNA

Phase of research

FDA-approved for Other Purpose

How it helps

Restore CFTR Function

General information

Amlexanox is an anti-inflammatory antiallergic immunomodulator. It was approved in 1996 in the USA but has been discontinued. Amlexanox is still used in Japan to treat aphthous ulcers of the mouth, bronchial asthma, allergic rhinitis, and conjunctivitis. In relation to cystic fibrosis, our AIM tool found the data that amlexanox helps produce full-length protein from nonsense mutation-CFTR.

Amlexanox on PubChem
Amlexanox on DrugBank
Amlexanonx on Wikipedia

Synonyms

N/A

Marketed as

N/A

Dietary sources

N/A

Structure not available

C16H14N2O4

Drug-Mutation Relation

Treats

Mutation Number of sources Average impact factor
nonsense mutations
1 4.32
Link Tested on Impact factor Notes
Rescue of nonsense mutations by amlexanox in human cells human cell cultures 4.32

Does not treat

Mutation Number of sources Average impact factor